Dr. Andreas Schatzlein

Biography

Andreas Schatzlein has a track record in medicines development and translational research spanning industry and academia. He trained as a veterinary surgeon (BVMS, Ludwig-Maximillian Universität München) and completed a PhD in Medical Biophysics at the Technical University of Munich, focusing on transdermal drug delivery using Transfersomes under the supervision of Prof. Gregor Cevc. In 1996, he joined Cancer Research UK at the Beatson Laboratories, University of Glasgow, where he led the Experimental Therapeutics Gene Medicines Group, focusing on advanced cancer therapeutics. He introduced good clinical laboratory practice (GCLP) standards in Europe’s largest oncology trial center, facilitating pharmacokinetics and pharmacodynamics assessment in Translational Clinical Trials. In 2006, he moved to the School of Pharmacy, University College London, where he continued developing novel cancer drugs and nanomedicines. Andreas became a full professor with the merger of the School into University College London in 2014. His research output includes 160 publications and 15 patents with an h-index of 40, focusing primarily on new medical therapies, particularly nano-enabled therapies at the pre-clinical and clinical levels. The goal of his research is to link fundamental mechanisms of chemical engineering and biomaterials to solve therapeutic challenges, ultimately translating this understanding into medical benefits. His research has attracted £25 million in funding from various bodies, including UK Research Councils and Innovate UK. Furthermore, he is the co-founder and CEO of Nanomerics Ltd., a specialty pharmaceutical company, known for its innovative nano-enabled products, such as NM127.

Research Interests

Experience

Awards

Patents